Morgan Ebert, Executive Editor

More than 20,000 water bead ingestions in children younger than 6 years were reported over 6 years, with some cases requiring surgery.

Modeling data suggest removing universal hepatitis B birth-dose vaccination could increase neonatal and chronic HBV infections in US infants.

Swedish trial data showed slow up-dosing peanut oral immunotherapy achieved sustained tolerance in most toddlers with peanut allergy.

Two-year data from the pivotal ApproaCH trial showed sustained growth improvements with TransCon CNP in pediatric achondroplasia.

New expert recommendations outline pediatric glucocorticoid dose reduction strategies after starting crinecerfont in classic CAH.

The review found no credible evidence linking HPV vaccination to serious adverse pregnancy outcomes or other long-term health risks.

Take a quick look at everything you may have missed in April, including the top FDA approvals and latest clinical updates.

FDA expands ASCENIV label to include pediatric patients aged ≥2 years with primary immunodeficiency, broadening earlier treatment access.

a2 Milk Company recalled 3 infant formula batches after detecting cereulide, a toxin that can cause rapid-onset gastrointestinal illness in infants.

FDA approved insulin glargine-aldy as an interchangeable biosimilar to Lantus for type 1 diabetes and adult type 2 diabetes.

FDA granted rare pediatric disease designation to investigational (Z)-endoxifen for McCune-Albright syndrome in girls.

Don Arnold, MD, MPH, highlights how a nurse-driven guideline reduced time to phototherapy in neonatal jaundice care.

Phase 3 data show berdazimer gel improved lesion clearance vs vehicle in molluscum contagiosum with a favorable safety profile.

A look back at the FDA submissions and regulatory decisions in the pediatric health care space from April 2026.

Raising pediatric flu vaccination to 70% could significantly reduce outpatient visits, hospitalizations, and deaths, easing strain on US systems.

HOPE perfusion showed early graft survival signals in pediatric partial-graft liver transplantation, but data remain limited to small reports.

Pilot study finds maternal dairy intake associated with lower levels of select human milk lipids, with unclear implications for infant health.

FDA testing of 312 infant formula samples found low or undetectable levels of contaminants, supporting safety and ongoing monitoring efforts.

The FDA cleared a generic Infuvite Pediatric injection for children receiving parenteral nutrition, adding a new option for hospital supply.

New AAP guideline replaces “failure to thrive” with “faltering weight,” emphasizing standardized diagnosis and targeted, less invasive care.

Autism diagnoses by primary care providers vary widely by region and state, highlighting disparities in access to specialty care.

Maternal RSV vaccination and nirsevimab were linked to lower infection rates and reduced severity in infants younger than 6 months.

MMR coverage remained below herd immunity 20 months after an Ohio outbreak, with minimal gains and persistent disparities in children.

FDA expands teplizumab (Tzeld) use to children as young as 1 year with stage 2 type 1 diabetes, aiming to delay progression to clinical disease.

Real-world data show pediatric hidradenitis suppurativa treatment relies on antibiotics, with delayed escalation and demographic differences in timing.

A pilot study finds diverse arthritis patterns and high metabolic comorbidity burden in idradenitis suppurativa, with IL-17 inhibitors showing improved outcomes.

David Stukus, MD, discusses nutrition risks, early allergen introduction, and evolving dietary strategies for managing pediatric food allergies.

Phase 3 KEPLER data showed vedolizumab achieved remission in nearly half of children with ulcerative colitis, with consistent safety and durable benefit.

Nontargeted analysis identified 42 PFAS in cord blood, revealing broader prenatal exposure than traditional testing methods capture.

New international pediatric HAE guideline recommends oral sebetralstat as first-line acute therapy for adolescents 12 years and older.